vs

Side-by-side financial comparison of Vontier Corp (VNT) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DENTSPLY SIRONA Inc. is the larger business by last-quarter revenue ($961.0M vs $808.5M, roughly 1.2× Vontier Corp). Vontier Corp runs the higher net margin — 15.3% vs -15.2%, a 30.5% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs 4.1%). Vontier Corp produced more free cash flow last quarter ($174.8M vs $60.0M). Over the past eight quarters, Vontier Corp's revenue compounded faster (3.4% CAGR vs 0.4%).

Vontier Corporation is an industrial manufacturing company headquartered in Raleigh, North Carolina. It owns the brands Gilbarco Veeder-Root, Matco Tools and Teletrac Navman, including subsidiaries Hennessy Industries, Gasboy, and Global Traffic Technologies (GTT).

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

VNT vs XRAY — Head-to-Head

Bigger by revenue
XRAY
XRAY
1.2× larger
XRAY
$961.0M
$808.5M
VNT
Growing faster (revenue YoY)
XRAY
XRAY
+2.1% gap
XRAY
6.2%
4.1%
VNT
Higher net margin
VNT
VNT
30.5% more per $
VNT
15.3%
-15.2%
XRAY
More free cash flow
VNT
VNT
$114.8M more FCF
VNT
$174.8M
$60.0M
XRAY
Faster 2-yr revenue CAGR
VNT
VNT
Annualised
VNT
3.4%
0.4%
XRAY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
VNT
VNT
XRAY
XRAY
Revenue
$808.5M
$961.0M
Net Profit
$123.5M
$-146.0M
Gross Margin
46.1%
Operating Margin
18.9%
-14.5%
Net Margin
15.3%
-15.2%
Revenue YoY
4.1%
6.2%
Net Profit YoY
0.0%
66.0%
EPS (diluted)
$0.85
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VNT
VNT
XRAY
XRAY
Q4 25
$808.5M
$961.0M
Q3 25
$752.5M
$904.0M
Q2 25
$773.5M
$936.0M
Q1 25
$741.1M
$879.0M
Q4 24
$776.8M
$905.0M
Q3 24
$750.0M
$951.0M
Q2 24
$696.4M
$984.0M
Q1 24
$755.8M
$953.0M
Net Profit
VNT
VNT
XRAY
XRAY
Q4 25
$123.5M
$-146.0M
Q3 25
$102.8M
$-427.0M
Q2 25
$91.9M
$-45.0M
Q1 25
$87.9M
$20.0M
Q4 24
$123.5M
$-430.0M
Q3 24
$91.8M
$-494.0M
Q2 24
$70.1M
$-4.0M
Q1 24
$136.8M
$18.0M
Gross Margin
VNT
VNT
XRAY
XRAY
Q4 25
46.1%
Q3 25
47.3%
48.8%
Q2 25
47.9%
52.4%
Q1 25
47.3%
53.0%
Q4 24
49.3%
Q3 24
47.2%
52.1%
Q2 24
48.2%
51.9%
Q1 24
49.2%
53.1%
Operating Margin
VNT
VNT
XRAY
XRAY
Q4 25
18.9%
-14.5%
Q3 25
18.9%
-24.1%
Q2 25
17.6%
-13.7%
Q1 25
17.6%
7.2%
Q4 24
19.2%
-56.2%
Q3 24
17.5%
-48.6%
Q2 24
16.4%
5.1%
Q1 24
18.8%
4.4%
Net Margin
VNT
VNT
XRAY
XRAY
Q4 25
15.3%
-15.2%
Q3 25
13.7%
-47.2%
Q2 25
11.9%
-4.8%
Q1 25
11.9%
2.3%
Q4 24
15.9%
-47.5%
Q3 24
12.2%
-51.9%
Q2 24
10.1%
-0.4%
Q1 24
18.1%
1.9%
EPS (diluted)
VNT
VNT
XRAY
XRAY
Q4 25
$0.85
$-0.74
Q3 25
$0.70
$-2.14
Q2 25
$0.62
$-0.22
Q1 25
$0.59
$0.10
Q4 24
$0.82
$-2.09
Q3 24
$0.60
$-2.46
Q2 24
$0.45
$-0.02
Q1 24
$0.88
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VNT
VNT
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$492.2M
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$1.2B
$1.3B
Total Assets
$4.4B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VNT
VNT
XRAY
XRAY
Q4 25
$492.2M
$326.0M
Q3 25
$433.8M
$363.0M
Q2 25
$364.2M
$359.0M
Q1 25
$333.6M
$398.0M
Q4 24
$356.4M
$272.0M
Q3 24
$330.9M
$296.0M
Q2 24
$331.3M
$279.0M
Q1 24
$406.0M
$291.0M
Total Debt
VNT
VNT
XRAY
XRAY
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
VNT
VNT
XRAY
XRAY
Q4 25
$1.2B
$1.3B
Q3 25
$1.2B
$1.5B
Q2 25
$1.2B
$2.0B
Q1 25
$1.1B
$2.0B
Q4 24
$1.1B
$1.9B
Q3 24
$1.0B
$2.5B
Q2 24
$1.0B
$3.1B
Q1 24
$984.9M
$3.3B
Total Assets
VNT
VNT
XRAY
XRAY
Q4 25
$4.4B
$5.4B
Q3 25
$4.4B
$5.7B
Q2 25
$4.4B
$6.1B
Q1 25
$4.3B
$6.0B
Q4 24
$4.3B
$5.8B
Q3 24
$4.3B
$6.6B
Q2 24
$4.2B
$6.9B
Q1 24
$4.3B
$7.1B
Debt / Equity
VNT
VNT
XRAY
XRAY
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VNT
VNT
XRAY
XRAY
Operating Cash FlowLast quarter
$190.1M
$101.0M
Free Cash FlowOCF − Capex
$174.8M
$60.0M
FCF MarginFCF / Revenue
21.6%
6.2%
Capex IntensityCapex / Revenue
1.9%
4.3%
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters
$441.1M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VNT
VNT
XRAY
XRAY
Q4 25
$190.1M
$101.0M
Q3 25
$110.5M
$79.0M
Q2 25
$100.0M
$48.0M
Q1 25
$110.4M
$7.0M
Q4 24
$168.1M
$87.0M
Q3 24
$121.8M
$141.0M
Q2 24
$46.1M
$208.0M
Q1 24
$91.5M
$25.0M
Free Cash Flow
VNT
VNT
XRAY
XRAY
Q4 25
$174.8M
$60.0M
Q3 25
$90.3M
$40.0M
Q2 25
$83.3M
$16.0M
Q1 25
$92.7M
$-12.0M
Q4 24
$148.0M
$36.0M
Q3 24
$103.2M
$98.0M
Q2 24
$22.3M
$156.0M
Q1 24
$71.3M
$-9.0M
FCF Margin
VNT
VNT
XRAY
XRAY
Q4 25
21.6%
6.2%
Q3 25
12.0%
4.4%
Q2 25
10.8%
1.7%
Q1 25
12.5%
-1.4%
Q4 24
19.1%
4.0%
Q3 24
13.8%
10.3%
Q2 24
3.2%
15.9%
Q1 24
9.4%
-0.9%
Capex Intensity
VNT
VNT
XRAY
XRAY
Q4 25
1.9%
4.3%
Q3 25
2.7%
4.3%
Q2 25
2.2%
3.4%
Q1 25
2.4%
2.2%
Q4 24
2.6%
5.6%
Q3 24
2.5%
4.5%
Q2 24
3.4%
5.3%
Q1 24
2.7%
3.6%
Cash Conversion
VNT
VNT
XRAY
XRAY
Q4 25
1.54×
Q3 25
1.07×
Q2 25
1.09×
Q1 25
1.26×
0.35×
Q4 24
1.36×
Q3 24
1.33×
Q2 24
0.66×
Q1 24
0.67×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VNT
VNT

Environmental Fueling Solutions Segment$387.5M48%
Services$191.0M24%
Repair Solutions Segment$144.5M18%
Other$85.5M11%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons